Fund managers running passive funds will be buying Medtecs!
Next milestone: LOOK out for transfer from Catalist to Mainboard. More fund managers will be able to buy Medtecs! (Most funds' mandate excludes Catalist stocks)
Medtecs has steadily progressed from when I first took notice of it at $1.23. CEO has done roadshows for SG investors, CEO bought 1 million shares, Company has applied to upgrade to Mainboard, Company will surely commence share buyback after getting a mandate soon. Soon!
Medtecs sits in a strong position with 200 hospitals world wide as customers, an extremely valuable relationship that can only translate into long-term business for Medtecs, and a strategic position to grow even further. There must be easily thousands of hospitals that can look to partner with Medtecs.
Medtecs shares have been sold off in recent months after achieving nearly $2.00, as the vaccine news came around and investor sentiment turned cautious. This gives investors a good chance to buy in.